Mcmaster University

Marstacimab, a recently FDA-approved monoclonal antibody targeting TFPI, showed significant reduction in bleeding rates for hemophilia A and B patients in the pivotal phase 3 BASIS trial.

Researchers at McMaster University and MIT have discovered enterololin, a narrow-spectrum antibiotic that specifically targets disease-causing bacteria in inflammatory bowel diseases while preserving beneficial gut microbiome.

BioLegacy Evaluative Group has filed a provisional patent with the USPTO for an innovative air-driven intranasal drug delivery device targeting emergency and self-administered pharmaceuticals.

A McMaster University-led international study analyzed 93 randomized controlled trials involving over 11,000 participants to identify the most effective treatments for chronic hives.

Fifty1 AI Labs successfully completed the REVIVE Adaptive Platform Trial, the largest and most rigorous Long COVID study to date, enrolling over 600 participants across multiple global sites.

McMaster University's inhaled COVID-19 vaccine demonstrated safety and immunogenicity in a Phase 1 trial of 36 healthy adults, with results published in Nature Communications.

The ACHIEVE trial, the largest study to date with 2,538 dialysis patients across 12 countries, found that spironolactone did not significantly reduce cardiovascular death or heart failure hospitalization compared to placebo.

The 62nd European Renal Association Congress in Vienna will present seven late-breaking clinical trials addressing chronic kidney disease, dialysis patients, and glomerular disease developments.

Late-breaking results from the CLEAR OASIS 9 trial reveal that colchicine failed to reduce cardiovascular events after myocardial infarction despite lowering inflammatory markers.

Researchers have identified lariocidin, the first new class of antibiotics to reach the market in nearly 30 years, discovered in bacteria from backyard soil samples.